Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center

BACKGROUND: We reported the clinical activity of gemcitabine plus capecitabine (GX) in mRCC pts previously treated with cytokines and targeted agents (Tannir et al. JU 2008). Bevacizumab (A) has activity in mRCC and has been successfully incorporated into several chemotherapy regimens in many tumor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BJU Int
Main Authors: Jonasch, Eric, Lal, Lincy S., Atkinson, Bradley J., Byfield, Stacey DaCosta, Miller, Lesley Ann, Pagliaro, Lance C., Feng, Chun, Tannir, Nizar M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648626/
https://ncbi.nlm.nih.gov/pubmed/21355978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2010.09626.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados